Human immunodeficiency virus (HIV) constitutes an unprecedented challenge to medical science. Once an HIV infection is established, its clinical course, while protracted, is generally inexorable. With the possible exception of a group of recently described "long-term nonprogressors," virtually all HIV-infected individuals eventually develop acquired immunodeficiency syndrome (AIDS), the outcome of which is almost invariably fatal.
The course of HIV infection is quite different from that encountered in the great majority of infectious diseases. The more normal experience in the contest between pathogens and their hosts is that of an acute infection in which some fraction of those infected recover and, thereafter, express solid immunity, protecting them against the same or related agents. Generally, the nature of protective immunity expressed by those that have recovered from infection may be used as a guide to the type of response that a vaccine should induce to provide protection. In the case of HIV, it has generally been believed that infected individuals never purge themselves of the virus, although this now appears to have been an oversimplification. The lack of information that would usually be provided by study of those who had recovered has meant that no correlation between type of immunity and protection could be drawn to guide scientists in their efforts to develop protective anti-HIV vaccines.
A Vigorous Immune Response Occurs in Response to HIV Infection
Does an effective immune response occur in infected individuals? Perhaps surprisingly, in view of the apparent inevitability of progression, the weight of evidence strongly suggests that a highly effective immune response does occur and that it contains the virus for a long period of time, although it rarely eradicates it. Infected individuals produce large amounts of anti-HIV antibody, the appearance of which has become the hallmark for the diagnosis of infection. Neutralizing antibody is commonly observed, although it is generally not detectable until after the initially high viral titers have fallen to the low levels that characterize the period of clinical latency (Robert et al., 1988; Sawyer et al., 1990) . Indeed, development of neutralizing antibody that is cross-reactive on HIV strains other than that causing the infection may be even more protracted. The role of such neutralizing antibody in the control of HIV in the infected individual is not truly understood. Indeed, we do not yet know whether the small subset of infected individuals who become long-term nonprogressors may show earlier and more vigorous production of neutralizing antibodies than do the great majority of individuals in whom infection is progressive.
In contrast with the pace of appearance of neutralizing antibody, cytotoxic T cells (CTLs) specific for epitopes in the envelope glycoprotein, the gag-derived proteins, and other HIV proteins (including the reverse transcriptase) can be detected quite early in infection (Walker et al., 1989) . Based mainly on the correlation of the time at which the initial viremia diminishes and at which CTLs can be detected, it is widely held that these cells, by killing virally infected cells prior to their production of additional infectious virus, are responsible for the striking diminution in viral burden (Walker, 1990) .
Does the Immune Response Ever Eliminate or Fully Control Infection?
The recognition that a vigorous immune response accompanies infection raises the issue of whether this response ever actually controls HIV. This has become a much more active subject of research with the appreciation that a set of HIV-infected individuals can survive for prolonged periods of time with essentially normal numbers of CD4 + T cells (Cao et al., 1995; Pantaleo et al., 1995; Kirchhoff et al., 1995) . It is quite likely that no single factor explains the control of infection in all long-term nonprogressors. Indeed, as I will discuss subsequently, some of these individuals may have been infected with a virus of limited replication competence, pathogenicity, or both (Kirchhoff et al., 1995) . However, many long-term nonprogressors appear to have been infected with pathogenic viruses that they have controlled (Huang et al., 1995) . Indeed, in many of these individuals, viral burden is very low (Cao et al., 1995) .
No definitive information yet exists to explain this control of HIV, but in many cases, long-term nonprogressors possess CD8 + T cells that strikingly limit the capacity of HIV from their CD4 ÷ T cells to infect peripheral blood mononuclear cells (PBMCs) that have been activated with phytohemagglutinin (PHA). Pure CD4 ÷ T cells from long-term nonprogressors are quite effective in transmitting HIV to PHA-activated PBMCs, but addition of their CD8 + T cells strikingly suppresses such infection. Levy and his colleagues (Mackewicz et al., 1994) have shown that supernatants of CD8 ÷ T cells can inhibit in vitro infection. They have argued that this CD8 cell-derived soluble factor, which appears to be distinct from any known cytokine, may act to limit infectability in vivo as well as in vitro. Whether this factor explains the lack of progression seen in long-term nonprogressors is unknown. Obviously, characterization of this factor is a priority goal.
The possibility that an HIV that had established an infection may then be eliminated has been raised by results from the study of a child from whom HIV was isolated neonatally but who was seronegative and had no recoverable virus nor any clinical symptoms at the age of 5 (Bryson et al., 1995) . This infant had positive viral cultures on two separate occasions in the first year of life, implying that he had acquired HIV from his mother during pregnancy or delivery. Thus far, we know little about the nature of the anti-HIV immune response made by this child nor do we know whether the infecting virus was fully virulent. The results of studies to answer these questions, to the extent that they are feasible, will be eagerly awaited.
An example consistent with immune elimination of HIV has been reported by Shearer and his colleagues (Pinto et al., 1995) . They studied a set of health care workers who had been exposed to HIV-contaminated blood and compared them with a similar number of individuals exposed to blood from uninfected individuals. None of those exposed to HIV + blood seroconverted, but this is not surprising since the likelihood of developing an established HIV infection from such an exposure is quite low. However, of 20 persons exposed to HIV-infected blood, 7 developed CTLs specific for HIV peptides in association with class I major histocompatibility complex (MHC) molecules. None of those exposed to uninfected blood had such CTLs.
The development of class I MHC-restricted, HIV-specific CTLs suggests that an actual HIV infection occurred. This conclusion is based on the cell biology of antigen presentation by class I MHC molecules (Germain and Margulies, 1993) . Class I-restricted antigen presentation generally requires endogenous production of the protein from which the peptide is derived. Such production of viral protein implies viral infection of the cells that evoked the HIVspecific CTLs. Since no evidence of infection could be detected in the exposed health care workers and CTLs were no longer discerned a year after exposure, it would appear that the period of putative HIV infection was transient. The relationship of the CTLs to the presumed purging of HIV is not established, although it would be quite plausible that the CTLs did eliminate the virus.
Shearer has argued that the reason these individuals were protected against the development of an established HIV infection is not only that small amounts of virus may present a challenge with which the immune system can cope but also because low doses of antigen may preferentially elicit a response dominated by the production of interferon~ (IFN~,) and of CTLs (Bretscher et al., 1992) . Indeed, Clerici et al. (1994) have reported that infection with very limited amounts of fully virulent simian immunodeficiency virus (SIV) can protect macaques against a subsequent challenge with a normally infectious dose of SIV.
An Established Infection with an Attenuated Virus May Induce Robust Immunity
The inference that protective immune responses occur quite commonly may be drawn from studies indicating the difficulty in superinfecting primates. Infections with attenuated viruses appear to result in a state of solid immunity protecting against subsequent infection with fully virulent virus. The most striking example of such protection is the robust resistance of macaques that have been infected with attenuated SIVs, such as those that are defective in the nef gene. Desrosiers and his colleagues (Daniel et al., 1992) have shown that these animals contain DNA sequences of the defective virus, although their viral burdens are very low. Despite the continued presence of the attenuated SIV, the macaques display striking resistance to infection with large amounts of fully virulent SIV. In other experiments, protection was observed not only against free SIV but also against SIV-infected cells (Almond et al., 1995) . The time required for induction of this resistance was quite long in the initial reports, but others have now observed that the period for attainment of resistance can be considerably shortened. Despite the solid resistance of these animals to infection, the nature of their immunity has not been determined. Indeed, it is possible that their resistance is not immunological at all, although that seems rather unlikely.
These results reveal a theme that characterizes most situations in which infections with live SIVs and HIVs induce protective immunity. Such protected individuals continue to harbor the "immunizing" virus. It seems paradoxical that a response powerful enough to prevent infection by a virulent virus cannot fully rid the host of an infection with an attenuated virus. There are precedents for this in the study of immune responses to tumors in which the concept of concomitant immunity, the ability to reject a transplant of a tumor identical to one borne by an animal, was developed. In both instances, principles of local immunity and of elimination of the pathogen in some particularly vulnerable state need consideration. Thus, it is possible that the effective immune status that nonetheless fails to purge existing virus may be quite effective in limiting the transmission of virus in the pool of cells in which virus normally turns over quite rapidly . By contrast, in cellular reservoirs in which the virus is retained for long periods of time (possibly macrophages), immunity may have very limited effectiveness. Other considerations may have to deal with the likelihood that establishing an infection may prove to be a considerably more difficult challenge for the virus than maintaining one. For example, local immunity at mucosal surfaces may prevent access of HIV to critical sites.
However, an important issue that needs further exploration is the possibility, indeed the likelihood, that solid immunity will only be observed as long as the attenuated virus is retained. There is considerable controversy in the immunological literature as to whether the retention of immunological memory requires the persistence of antigen (Grossman and Paul, 1992) . Closely related is a controversy over how long a memory cell is retained without proliferation. Is memory a property of a long-lived nonproliferating cell, or is continued antigenic stimulation required to retain the state of immunological memory? If the latter is the case, viruses that are so attenuated that they cannot replicate sufficiently to sustain their presence in the host will probably fail to induce a state of protective immunity. Indeed, I will return to this point later in considering the potential pathogenicity of attenuated viruses.
Chimpanzees may also display an apparently comparable state of immunity. Chimpanzees are resistant to the induction of disease by HIV-1; accordingly, those infected with the LAV/IIIB (IIIB) strain of HIV-1 fail to develop any evidence of disease. Recently, Martin and his colleagues have isolated a strain of HIV-1, DH12, that appears to elicit greater viral burdens in chimpanzees than other strains of HIV (Shibata et al., 1995) . Chimpanzees inoculated with DH12 can display lymphadenopathy. Chimpanzees pre-viously infected with IIIB are resistant to infection even with very large amounts of DH12. Just as was the case with the macaques infected with attenuated SlV, these chimpanzees, although resistant to DH 12, continue to express IIIB sequences. Thus, an inability to purge an existing virus coexists with a state of solid immunity capable of preventing (or perhaps eliminating) a new infection, even with a more virulent virus. However, not all infections with one HIV prevent superinfection with another (Fultz et al., 1994) ; what the determinants are that distinguish the two sets of observations has not yet been clarified.
These results are consistent with the general experience that virus isolated from most HIV-infected adults appears to represent the quasispecies that could have emerged from a single infecting virus (Saag et al., 1988) . Since many HIV ÷ individuals have been exposed to virus from more than one infected individual, the presence of but a single type of H IV suggests that, once infected, resistance to a second infection occurs. Indeed, this would be consistent with the concept that even highly virulent HIV may elicit an immune response that prevents infection with another HIV, but that fails to purge the existing virus. One must interpret this indirect argument with some care; an alternative explanation would be that one virus is selected from many because of its superior "fitness" and comes to dominate a host despite the possibility that several viruses may have infected the individual, either simultaneously or sequentially. Indeed, there is persuasive evidence that viruses exist that must have arisen by recombination from "parents" of two different clades (Robertson et al., 1995) . Such recombination would require a coinfection (simultaneous or sequential) of a single host with distinct viruses.
Unfortunately, we know very little about the nature of the protective immunity induced by an infecting virus. Cell transfer experiments, the classical tool for evaluating the cellular elements underlying an immune response, are not generally feasible in macaques, except in the unusual situation in which twins exist. Indeed, the full value of the SIV/ macaque model as a tool for understanding the nature of the pathogenesis of lentivirus infection and the nature of protective immunity will not be realized unless techniques are developed for the routine twinning of macaques so that genetically identical individuals exist between whom cells can be transferred without rejection. Serum transfers have been carried out, revealing that sera from monkeys infected with virulent SIV can protect naive cynomolgus monkeys against infection (Putkonen et al., 1991) . This result indicates the potential importance of antibody in protection against infection. Whether sera from macaques infected with nef-deficient SIV has similar protective capacity is not yet known.
Do Humans Display Immunity Induced by Attenuated HIVs?
Attenuated HIVs have been recovered from humans in whom infection has had a very benign course. Desrosiers and his colleagues (Kirchhoff et al., 1995) described one such individual with no sign of disease and a normal CD4 cell count more than 10 years after infection. Molecular analysis of the patient's HIV-1 over this extended period revealed a deletion in the nef gene that was sustained and, indeed, extended. Another interesting example is provided by a set of individuals in Australia each infected by blood products from a single donor (Learmont et al., 1992) . All of those infected in this way displayed a benign course with the exception of one who was being treated with glucocorticoids for systemic lupus erythematosus.
Can attenuated viruses yield a state of concomitant immunity in humans? The examples cited do not offer formal proof that the attenuated viruses induce protective immunity in humans. That would require that subjects infected with an attenuated virus were resistant to a challenge with a fully virulent virus that would infect most nonprotected individuals. However, there are some provocative observations that suggest that HIV-2 may induce such immunity, protecting against infection with HIV-1 (or controlling HIV-1 infection). HIV-2 is a less virulent lentivirus, related to HIV-1, that is being transmitted in some areas in Africa in which HIV-1 is also found. Among a set of prostitutes in the Gambia, a group have been identified that have appeared to escape HIV-1 infection despite several years of potential exposure to HIV-l-infected sex partners (Rowland-Jones et al., 1995) . Many of these women have CTLs that recognize peptides shared by HIV-1 and HIV-2, suggesting that an inapparent infection with HIV-2 may have elicited an immune response capable of cross-protection.
This indirect experiment receives support from a recent epidemiological study conducted on another group of prostitutes in Dakar, Senegal, from 1985 (Travers et al., 1995 . They were segregated into H IV-2 ÷ and HIV-2-groups, and the risk of subsequent infection with HIV-1 was determined for the two groups. Over an extended period of observation, the relative risk of infection with HIV-1 of the H IV-2 ÷ women was one third that of the H IV-2-women. The possibility that the HIV-2 + women might have altered their behavior so as to be at lower risk of subsequent HIV-1 infection was considered. It was argued that rates of infection with other sexually transmitted microorganisms would provide an observational test of whether such behavior modification had occurred. The result was that the HIV-2 ÷ women had a rate of sexually transmitted diseases at least as great as the HIV-2-women. Thus, the most likely explanation is that infection with HIV-2 provided a state of immunity that protected some of these women against infection with HIV-I.
Could Attenuated HIVs Form the Basis of Vaccines?
In view of the relatively disappointing outcomes that have been obtained thus far with other vaccine candidates, the results of these experiments create inevitable enthusiasm for the possible use of attenuated live HIVs as protective vaccines. Unfortunately, the barriers to such use are quite daunting. It would have to be demonstrated that the risk of the virus reverting to its virulent state would be very low and that the deletions used to attenuate the virus actually rendered the virus nonpathogenic. The latter is not a trivial point, since we do not yet understand the determinants of pathogenicity. The major determinant of pathogenicity of H IVs and SIV may be their capacity to replicate; alternatively, specific gene products may be required for induction of the disease even in the face of replication competence (Coffin, 1995) . Thus far, the test in preparing attenuated viruses has been diminished replication competence of the virus. However, if that criterion were to prove inadequate, it is possible that recovery of virulence might occur under unanticipated circumstances.
Indeed, a rather dramatic example of unanticipated virulence of an attenuated virus has recently been reported. Ruprecht and her colleagues (Baba et al., 1995) showed that an SIV in which there was a deletion in the nefgene, as well as in vpr, although strikingly attenuated in adult macaques, was capable of initiating infection and disease when fed in large amounts to neonates within 1 hr of birth. While the reasons for the susceptibility of the neonates was not established, it seems likely that the immaturity of their immune systems and their relative immunoincompetence may explain it. indeed, it is well known that many murine oncogenic retroviruses must be inoculated into neonates if tumors are to be induced; adults generally make a vigorous immune response and eliminate the virus (Weiss et al., 1984) .
Would the risk of transmission from a woman vaccinated with an attenuated virus to her infant rule out the use of such viruses as vaccines? One could easily imagine that this problem could be mitigated by avoiding the vaccination of pregnant women. While it is anticipated that the attenuated virus would persist in the vaccinee, once the initial infection has been controlled viral titers should be exceedingly low, as they are in adult macaques that have been infected with nef-defective SIV. Thus, the chance of transmission, which appears to be linked to viral burden, is likely to be very low.
However, this does not mean that the implications of this experiment do not constitute a serious impediment to the introduction of an attenuated live HIV vaccine. If the proper explanation for the susceptibility of neonates is their relatively immunoincompetency, there would have to be a serious concern about the potential susceptibility of immunosuppressed adults or adults that are immunocompromised for other reasons. Furthermore, since activated CD4 cells appear to be particularly susceptible to HIV infection, it is conceivable that the balance between HIV control and growth might be tipped in the course of an intercurrent infection, in which vigorous T cell activation may be occurring.
The bottom line of this consideration of the potential usefulness of attenuated live HIV vaccines in humans is that extensive safety testing would certainly be required before such use could be considered in any large population. Safety testing would inevitably carry a substantial risk and would have to meet very high ethical standards. Possibly, individuals who were members of groups at very high risk of infection and in whom behavior modification strategies had failed might be potential participants in such trials. Under any set of circumstances, such trials would have to start with small numbers and would eventually require quite long observational periods, not only because of the risk of the recovered virulence of the virus after long periods of time, possibly late in life with the immunodeficiency of old age, but also because insertional mutagenesis might increase the likelihood of neoplasms.
Thus, attenuated viruses have provided the most robust protection against infection with virulent virus. Nonetheless, it has not been unequivocally established that the protection is immunological. Assuming that it is, the immune mechanisms that account for it are still not known. Establishing efficacy will be sufficiently daunting that only in settings with a very high transmission rate is it likely that such a vaccine could be used, at least initially. On the other hand, the need to establish the immunological mechanisms underlying this protection is paramount. Clearly, we now have an example in macaques and possibly in HiV-2-infected humans of a state of protective immunity. In that respect, we are now closer than before to developing an understanding of the nature of immune protection against HIV. Understanding the basis of protection would obviously provide a standard to help in guiding the development of other vaccine candidates.
Prospects for Immunological Control of HIV
Although a complete review of vaccine strategies that could be used for HIV is beyond the scope of this review, certain key issues certainly bear discussion. The issue of whether subunit vaccines could be effective has not been resolved, but the first generation attempts with soluble gp120 preparations used either with alum or with MF59 (an oil in water adjuvant) have proved disappointing. That is not to imply that such vaccines fail to evoke an immune response or that, under certain very specified conditions, they do not elicit protection. Indeed, subjects immunized with several courses of gp120 do develop antibodies reactive with the immunizing viral strain, although titers tend to decline rapidly after each boost. The titers against other strains tend to be substantially lower than those against the immunizing strain (Schwartz et al., 1993) . There is also considerable controversy regarding the neutralizing capacity of the elicited antibody. When tested against tissue culture-adapted strains of HiV and in assays measuring infection of established cell lines, sera from immunized subjects often display a substantial neutralizing titer. However, when clinical isolates are used as a source of virus and PBMCs as the target cells, little or no neutralizing capacity of the sera are observed. Whether this reflects a physiologically important difference and which of the two assays is more relevant to in vivo infection are not clear.
It is true that a series of chimpanzees that had received several courses of prior immunization with a gp120 preparation were protected against a challenge with HIV administered shortly after their last immunization (Berman et al., 1990; Duliege, 1994) . This could reflect a stronger neutralizing capacity than that suggested by in vitro assays. Alternatively, and rather more likely, it could be explained by the fact that chimpanzees do not support a high degree of viral replication and, thus, should provide a particularly easy setting in which to eliminate virus.
In any case, a decision not to proceed to efficacy testing in the United States with this preparation has been made, although a World Health Organization expert committee has recommended trials with gp120 preparations in areas with high transmission rates, such as Thailand. Currently, much effort is being expended on canarypox vectors into which HIV genes, such as gag, pol, and env, have been cloned. Primary immunization with such recombinants together with boosts with soluble gp120 has been suggested based on experience in macaques. Unfortunately, initial studies with canarypox recombinants indicate that they may be of less than optimal immunogenicity (Plotkin, 1994) , possibly because they fail to replicate in human cells (Cox et al., 1993) . However, recombinants based on other pox viruses or possibly other viral vectors that support substantially greater replication may prove more effective as immunogens. Other approaches, such as the use of naked DNA specifying HIV antigens and eliciting the expression of cellular costimulants (such as B7), are also receiving considerable attention. Unfortunately, without further understanding of the means through which attenuated vaccines elicit protection, we will be forced to make certain major assumptions as to the type of immunity that is likely to be protective and to design immunization protocols that appear most likely to elicit this form of immunity.
An obvious area to examine is whether influencing the quality of an immune response might enhance the protective value of those responses. Two important subjects are the control of the balance of cytokines that are produced and the enhancement of the degree of expression of immunity at mucosal surfaces.
Favoring the induction of HIV-specific IFNy-producing T cells and CTLs over T cells that mainly produce interleukin-4 (IL-4) and related cytokines, including IL-5 and IL-10, has been strongly suggested not only as an immunization strategy but also as a means to make ongoing immune responses in infected individuals more effective. Studies in experimental animals suggest that the regulation of the quality of immune responses, while it may be influenced by antigen dose, as Shearer has already indicated, is controlled principally by the cytokines available at the time of priming (Paul and Seder, 1994) . In particular, IL-4 appears to inhibit priming for IFNy production by T cells and IL-12 appears to strikingly enhance priming for IFNy production. Whether the use of cytokines in vaccine protocols would be effective and, if effective, feasible remains to be determined.
The enhancement of mucosal immunity, particularly at the sites where transmission normally occurs, has been emphasized as an important goal in preventing transmission. Strategies that may elicit such enhanced mucosal responses include immunization at mucosal sites, the use of vectors, such as poliovirus (Andino et al., 1994) , that may favor induction of mucosal immunity (Cox et al., 1993) , and the use of cholera toxin B subunit as an adjuvant, which may aid in the development of mucosal immunity (Vajdy and Lycke, 1992) .
Conclusion
Experience thus far strongly indicates that solid immunity to HIV and SIV can be generated most effectively by living viruses. The epidemiological evidence that HIV-2 infection may offer protection against infection with HIV-1 implies that a substantial degree of cross-protection is possible, indicating that HIV mutational variability may not be as serious a problem as we had feared. For the moment, it seems unlikely that live attenuated viruses will come into use as vaccines in the developed world; whether particularly high risk areas of the developing world may constitute sites where such vaccines could be used ethically will remain to be seen. Thus, while it is essential that experiments go forward to clarify the nature of protection to SlV, in the short run the main goal of such experiments will be to understand the mechanism of immunity in the hope that it can be duplicated by other vaccines. In view of the world-wide nature of the AIDS epidemic and the fact that most infected individuals live in parts of the developing world in which drug therapy may prove to be too expensive for routine use, the importance of effective vaccines cannot be overstated. Moreover, prevention of transmission opens the possibility for the control of the epidemic, which is unlikely to be achieved by any therapeutic strategy.
